Timing Matters: Caution and Opportunity in Early Vasopressin for Septic Shock

Q: Why is the timing of vasopressin initiation important in septic shock?

The letter emphasizes that when vasopressin is started can strongly influence critical care outcomes, making the timing question central for clinicians managing septic shock.

Q: What concerns do the authors raise about the evidence supporting early vasopressin?

They note that only one included study was an RCT and most analyses were retrospective with meaningful risk of bias, plus the 6-hour “early” threshold is arbitrary and defined differently across studies.

Q: What safety limitations are highlighted regarding early vasopressin?

Safety data are limited, and clinically relevant ischemic complications such as digital or mesenteric ischemia were inconsistently reported and remain insufficiently investigated.

Q: What future studies does the letter recommend?

The authors call for adequately powered pragmatic RCTs with stratification by time since shock onset and norepinephrine dose thresholds, use of perfusion-based markers to guide personalized timing, and systematic reporting of ischemic and renal adverse effects.

Sep 30, 2026

Uploaded by Rizky

Letter to the editor responding to Bhattacharjee et al.’s systematic review and meta-analysis on how vasopressin initiation timing affects outcomes in septic shock. The authors commend methodological rigor, trial sequential analysis, and clinically encouraging pooled results for early (<6 hours) vasopressor initiation on ICU mortality, hospital stay, and renal replacement therapy need. They also highlight key limitations: mostly retrospective evidence, an arbitrary 6-hour threshold, heterogeneous timing definitions, limited safety reporting for ischemic complications, and inconclusive benefit signals. The letter proposes future pragmatic trials using stratified timing, perfusion markers, and systematic adverse-event reporting to clarify organ dysfunction trajectories.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Letter to the Editor: Timing Matters

Rationale for vasopressin timing in septic shock

Limitations in current evidence

Safety considerations and interpretive cautions

Future research directions

Practical interpretation until further data

LETTER TO THE EDITOR Timing Matters: Caution and Opportunity in Early Vasopressin for Septic Shock Habib Md R Karim1, Ankur Khandelwal2, Bheemas Atlapure3, Azeez Aspari4 Keywords: Distributive shock, Early sepsis, ICU outcomes, Vasopressin. Indian Journal of Critical Care Medicine (2025): 10.5005/jp-journals-10071-25108 Dear Editor, We read Bhattacharjee et al.’s systematic review and meta-analysis (SRMA) exploring the influence of vasopressin initiation timing on outcomes in septic shock patients with interest.1 For all critical care physicians, the question—when to start vasopressin is crucial. Thus, the SRMA exploring the little-known aspects of septic shock management is commendable. The SRMA is methodologically robust, focused on including the studies. Further, trial sequential analysis (TSA) increased statistical reliability. The pooled findings of early (<6 hours) vasopressor initiation on intensive care unit (ICU) mortality, hospital stay, and need for renal replacement therapy (RRT) are also clinically encouraging for adoption in practice. Although these results resonate with the vasopressin-sparing benefits hinted at in the VASST trial and the renal protection suggested by the VANISH trial; a few aspects still merit careful interpretation before practice recommendations.2, 3 First, only one included study was a randomized controlled trial (RCT); the remainder were retrospective analyses with moderateto-serious risk of bias, making confounding by indication almost inevitable. Second, the 6-hour “early” threshold, though pragmatic, remains arbitrary. The definition of timing varied—from shock onset to first norepinephrine administration or hospital presentation—each reflecting distinct physiological and logistical contexts. Early vasopressin started in the Emergency Department may differ profoundly in impact and safety from early use within 6 hours of ICU admission. Third, safety data are limited.4 Vasopressin is a strong vasoconstrictor, and some clinically relevant complications, such as digital or mesenteric ischemia, were inconsistently reported and remain to be investigated. Furthermore, although the SRMA met conventional significance, the TSA line indicates that the evidence for benefits remains inconclusive. These findings reiterate the similar outcomes and limitations to a previous analysis with 23 studies (only 2 RCTs) conducted in 2023.5 Therefore, we believe that future research should focus on: (A) adequately powered pragmatic RCTs stratified by both time since shock onset and norepinephrine dose thresholds; (B) integration of perfusion-based markers such as diastolic arterial pressure, diastolic shock index, or vasopressor-to-norepinephrine ratio index (VNERi) to guide personalized timing; and (C) systematic reporting of ischemic and renal adverse effects. Such designs would clarify whether early vasopressin truly alters the organ dysfunction trajectory or merely reflects clinician preference and patient phenotype. Until such data are available, we should interpret early vasopressin signals as promising yet hypothesis-generating, balancing potential catecholamine-sparing and RRT advantages against unquantified ischemic risk. Nevertheless, the Bhattacharjee et al.’s work and 1–3Department of Anesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India 4Department of Anesthesia, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Corresponding Author: Habib Md R Karim, Department of Anesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India, Phone: +91 9612372585, [e-mail: drhabibkarim@gmail.com](e-mail: drhabibkarim@gmail.com) How to cite this article: Karim HMR, KhandelwalA, Atlapure B, AspariA. Timing Matters: Caution and Opportunity in Early Vasopressin for Septic Shock. Indian J Crit Care Med 2025;29(12):1058 . Source of su

FAQs

Why is the timing of vasopressin initiation important in septic shock?

The letter emphasizes that when vasopressin is started can strongly influence critical care outcomes, making the timing question central for clinicians managing septic shock.

What concerns do the authors raise about the evidence supporting early vasopressin?

They note that only one included study was an RCT and most analyses were retrospective with meaningful risk of bias, plus the 6-hour “early” threshold is arbitrary and defined differently across studies.

What safety limitations are highlighted regarding early vasopressin?

Safety data are limited, and clinically relevant ischemic complications such as digital or mesenteric ischemia were inconsistently reported and remain insufficiently investigated.

What future studies does the letter recommend?

The authors call for adequately powered pragmatic RCTs with stratification by time since shock onset and norepinephrine dose thresholds, use of perfusion-based markers to guide personalized timing, and systematic reporting of ischemic and renal adverse effects.

Sep 30, 2026

Uploaded by Rizky